Navigation Links
Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program

ALBUQUERQUE, N.M., Dec. 21, 2010 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, today announced that it has been awarded $400,000 in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.  Proceeds from the grants will be used to advance the development of biomarker studies underway, one of which is to determine patient responsiveness to anti-TNF therapy, a drug used to treat inflammatory diseases such as Inflammatory Bowel Disease (IBD) and its sub-types, Ulcerative Colitis (UC) and Crohn's Disease (CD).

Genomic tests are becoming an integral component of accurate disease prevention, risk evaluation, diagnosis, management, and treatment.  Laboratories such as Exagen play a critical role in bringing novel molecular genomic tests to the medical community.

"This award recognizes Exagen's unique discovery and development efforts in molecular diagnostics," said Scott Glenn, Exagen CEO.  "Our anti-TNF discovery will lead to targeted treatment options for GI, Rheumatoid Arthritis, and Psoriasis patients with chronic inflammation.  Our research may also provide insight into targeted dosing levels, drug intervals, and drug options—all of which today are optimized through trial and error."

Exagen recently launched its initial suite of internally developed molecular diagnostic tests for IBD, UC, CD, and Irritable Bowel Syndrome.  Until these tests were delivered to the market, no genetic testing was available for these disease states. The most widely used tests were serology-based with sensitivities of 51 to 74%.  The Exagen molecular diagnostic tests achieve 84 to 92% sensitivity.

About Exagen Diagnostics, Inc.

Exagen Diagnostics is the emerging leader in laboratory-discovered and developed diagnostic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit

SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
2. Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash
3. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
4. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
5. The Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities in Personalized Medicine
6. bioMerieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
7. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
8. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
9. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
10. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
11. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
Post Your Comments:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation President ... and Astronomy, has been selected for membership in ARCS Alumni Hall of Fame ... Prize in Fundamental physics for the discovery of the accelerating expansion of the universe, ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography (sEMG) ... tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase III ...
(Date:10/7/2017)... WA (PRWEB) , ... October ... ... industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution ... ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Biology News(10 mins):